Loading...
Market
Impact on Novo Holdings' stock price following FTC decision on Catalent acquisition
3
Resolution / Starting Odds
Increase • 33%
Decrease • 33%
No significant change • 34%
Stock market data, financial news reports
Story
FTC Extends Review of Novo Holdings' $16.5 Billion Catalent Acquisition
May 3, 2024, 03:05 PM
The U.S. Federal Trade Commission (FTC) has issued a second request for more information regarding the $16.5 billion acquisition of Catalent by Novo Nordisk's parent company, Novo Holdings. This move, part of an extended antitrust review, could delay the deal by an additional 30 days. The request reflects the FTC's ongoing scrutiny of the transaction amid concerns from other pharmaceutical groups and contract manufacturers.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Stock price increases • 33%
Stock price decreases • 33%
No significant change in stock price • 34%
Increase • 33%
Decrease • 33%
No Significant Change • 34%
Stock price increases by more than 20% • 25%
Stock price increases by 10-20% • 25%
Stock price increases by less than 10% • 25%
Stock price decreases • 25%
Significantly positive • 33%
Moderately positive • 34%
No significant change • 33%
Increase over 10% • 33%
Decrease • 33%
Little to no change • 34%
Stock price increase • 33%
Stock price decrease • 33%
No significant change • 34%
Significant increase in Alphabet's stock price • 33%
Little to no change in Alphabet's stock price • 33%
Decrease in Alphabet's stock price • 33%
Increase • 33%
Decrease • 33%
No significant change • 34%
Increase by more than 5% • 25%
Increase by less than 5% • 25%
Decrease by less than 5% • 25%
Decrease by more than 5% • 25%